Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force

…, M Decramer, T Higenbottam… - European …, 1995 - Eur Respiratory Soc
Chronic obstructive pulmonary disease (COPD) is a disorder characterized by reduced
maximum expiratory flow and slow forced emptying of the lungs; features which do not …

The role of thrombosis in severe pulmonary hypertension

…, E Weitzenblum, T Higenbottam - European Respiratory …, 1996 - Eur Respiratory Soc
Considering the important surface in pulmonary circulation where blood can interact with the
endothelium, the maintenance of blood fluidity through the lung, by antithrombotic pathways …

Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension

J Pepke-Zaba, TW Higenbottam, AT Dinh-Xuan… - The Lancet, 1991 - Elsevier
The acute effects of inhaled nitric oxide (NO)(40 ppm in air) on pulmonary (PVR) and
systemic (SVR) vascular resistance were compared with those of an intravenous infusion of …

[HTML][HTML] Inhaled iloprost for severe pulmonary hypertension

…, G Simonneau, N Galiè, T Higenbottam… - … England Journal of …, 2002 - Mass Medical Soc
Background Uncontrolled studies suggested that aerosolized iloprost, a stable analogue of
prostacyclin, causes selective pulmonary vasodilatation and improves hemodynamics and …

A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung …

…, T Egan, MI Hertz, T Higenbottam… - The Journal of heart …, 1993 - europepmc.org
A clinically applicable, standardized method for assessing functional results after lung
transplantation is required to evaluate factors that may affect long-term outcome, to permit …

[HTML][HTML] Appetite-suppressant drugs and the risk of primary pulmonary hypertension

…, J Benichou, X Kurz, T Higenbottam… - … England Journal of …, 1996 - Mass Medical Soc
Background Recently in France, primary pulmonary hypertension developed in a cluster of
patients exposed to derivatives of fenfluramine in appetite suppressants (anorexic agents) …

Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the …

…, P Dartevelle, S Haworth, T Higenbottam… - European heart …, 2004 - academic.oup.com
Level of Evidence A Data derived from multiple randomised clinical trials or meta-analyses
Level of Evidence B Data derived from a single randomised clinical trial or large non …

[HTML][HTML] Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease

AT Dinh-Xuan, TW Higenbottam… - … England Journal of …, 1991 - Mass Medical Soc
Background. Endothelial cells release endothelium-derived relaxing factor (EDRF) in a
variety of vascular beds, including the pulmonary circulation. However, the role of EDRF …

Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort

…, PPW Hekking, T Higenbottam… - European …, 2015 - Eur Respiratory Soc
U-BIOPRED is a European Union consortium of 20 academic institutions, 11 pharmaceutical
companies and six patient organisations with the objective of improving the understanding …

Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family

…, J Newman, L Wheeler, T Higenbottam… - Journal of medical …, 2000 - jmg.bmj.com
BACKGROUND Primary pulmonary hypertension (PPH), resulting from occlusion of small
pulmonary arteries, is a devastating condition. Mutations of the bone morphogenetic protein …